Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pediatric phase I trial of LMB-2 [anti-tac-fv-PE38-conjugate] for refractory CD25-positive leukemias and lymphomas.

Next Previous
X
Search
Trial Profile

Pediatric phase I trial of LMB-2 [anti-tac-fv-PE38-conjugate] for refractory CD25-positive leukemias and lymphomas.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-Tac Fv PE38 conjugate (Primary)
  • Indications Leukaemia; Lymphoma
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 30 Apr 2015 Biomarkers information updated
    • 20 Oct 2008 'National Cancer Institute - Center for Cancer Research-Medical Oncology' added as study sponsor as reported by ClinicalTrials.gov.
    • 01 Jan 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top